A Piece Of The Puzzle Missing From Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Share Price
It's not a stretch to say that Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) price-to-earnings (or "P/E") ratio of 34.4x right now seems quite "middle-of-the-road" compared to the market in C
Freda (600223.SH) announced first-quarter results, net profit of 59.04 million yuan, a year-on-year decrease of 54.35%
Freda (600223.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 8.91 during the reporting period...
Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Market Cap Dropped CN¥539m Last Week; Private Companies Bore the Brunt
Key Insights Significant control over Lushang Freda PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions 53%
Concerns Surrounding Lushang Freda PharmaceuticalLtd's (SHSE:600223) Performance
Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) healthy profit numbers didn't contain any surprises for investors. We think this is due to investors looking beyond the statutory profits and bei
Freda (600223.SH): Net profit in 2023 increased 567.44% year-on-year, and plans to distribute 1 yuan for 10 shares
Glonghui, March 21丨Freda (600223.SH) released its 2023 annual report. Operating revenue was 4.579 billion yuan, down 64.65% year on year, net profit of 303 million yuan, up 567.44% year on year, after deducting non-net profit of 139 million yuan, up 137.40% year on year, with basic earnings of 0.30 yuan per share. A cash bonus of 1 yuan is distributed for every 10 shares.
Cinda Securities: Steady growth in large domestic sunscreen products, focus on leading cosmetics companies with alpha opportunities
Advances in technology of domestic brands and accurate grasping of consumer trends will help domestic sunscreen products occupy more market share.
Despite the Downward Trend in Earnings at Lushang Freda PharmaceuticalLtd (SHSE:600223) the Stock Climbs 5.4%, Bringing Five-year Gains to 157%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. Long term Lushang Fre
Cinda Securities: Looking at the development opportunities of domestic cosmetics brands from the successful overseas experience of e.l.f. Beauty (ELF.US)
Since 2019, E.L.F.Beauty's performance has grown rapidly and its stock price has risen significantly.
Lushang Service (02376) plans to acquire all shares in Shandong Lujian from Lushang Freda for 4.883 million yuan
Lushang Service (02376) issued an announcement. On February 27, 2024 (after the Stock Exchange trading session), the company (...
Freda (600223.SH): The holding subsidiary plans to transfer 100% of Huibangda's shares
Gelonghui, Feb. 27丨Freda (600223.SH) announced that the holding subsidiary Lushang Life Service Co., Ltd. plans to transfer 100% of its shares in Shandong Huibangda Decoration Engineering Co., Ltd. (“Shandong Chengfa Company”) to Shandong Urban and Rural Development Group Co., Ltd. (“Shandong Chengfa”). The transaction price was determined to be RMB 21.864 million based on the assessed value. After the transaction is completed, Lushang Service will no longer hold shares in Huibangda.
Lushang Freda PharmaceuticalLtd (SHSE:600223) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
The Market Doesn't Like What It Sees From Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Revenues Yet As Shares Tumble 28%
Unfortunately for some shareholders, the Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) share price has dived 28% in the last thirty days, prolonging recent pain. Instead of being rewarded, sh
Calculating The Intrinsic Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Lushang Freda PharmaceuticalLtd fair value estimate is CN¥7.65 Lushang Freda PharmaceuticalLtd's CN¥8.44 share price indicates it is trading
Freda (600223.SH): Net profit forecast to increase 472% to 538% in 2023
Gelonghui, January 23 | Freda (600223.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, net profit attributable to shareholders of listed companies is expected to be 260 million yuan to 290 million yuan in 2023. Compared with the same period last year, it will increase 214.54 million yuan to 244.54 million yuan, an increase of 472% to 538% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be RMB 116 million to RMB 146 million in 2023. Compared with the same period last year, it will increase 57.5 million yuan to 87.5 million yuan
Open source securities: solid fundamentals superimposed on emotional and financial catalysts in 24 years, and the beauty protection sector is expected to show better resilience
The core reason for the recent strong performance of the US care sector is the recovery in investment sentiment in the consumer sector, the market's tendency to allocate capital to a sector where performance is guaranteed, and the decline surpassed 2023.
Are Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
It is hard to get excited after looking at Lushang Freda PharmaceuticalLtd's (SHSE:600223) recent performance, when its stock has declined 8.3% over the past month. We, however decided to study the
Cinda Securities: Downstream application scenarios continue to enrich, optimistic about the beta market of recombinant collagen racetracks
With the launch of more high-quality products and enhanced C-side education, consumer awareness of recombinant collagen is expected to continue to increase.
Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Lushang Freda Pharmaceutical Co.,Ltd.'s (SHSE:600223) price-to-sales (or "P/S") ratio of 1.2x right now seems quite "middle-of-the-road" for companies in the Real Estat
Freda (600223.SH): No amino-peptide products are currently being produced
On December 15, Gelonghui (600223.SH) said on an interactive platform that the company currently does not produce aminopeptide products. In the third quarter of this year, the company's tadalafil tablets obtained a drug registration certificate and achieved sales.
Freda (600223.SH): Plans to transfer 90% of Freda Health Investment's shares for 208.25,800 yuan
Gelonghui (600223.SH) announced on December 12|Freda () announced that in order to focus on the development of the main business and continuously improve the quality of the company, the company plans to transfer 70% of Freda Health Investment's shares and 20% of Freda Health Investment's shares held by Freda Pharmaceutical Group, a wholly-owned subsidiary of the company, to Shandong Lushang Group Industrial Investment Co., Ltd., and the transaction price was determined at 20,825,800 yuan based on the assessed value. After the transaction is completed, the company will no longer hold shares in Freda Health Investments.
No Data